PanGen gains Malaysian approval for epoetin alfa biosimilar

Biosimilars/News | Posted 15/02/2019 post-comment0 Post your comment

South Korea-based biotechnology company PanGen Biotech (PanGen) announced on 7 February 2019 that Malaysia’s National Pharmaceutical Regulatory Agency has granted sales approval for Erisa, an epoetin alfa biosimilar.

Erythropoietin V13F07

Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia, commonly associated with chronic renal failure and cancer chemotherapy.

PanGen made a deal with Malaysia-based Chemical Company of Malaysia Berhad (CCM), wholly owned subsidiary of CCM Duopharma Biotech Berhad, to carry out a clinical trial of biosimilar erythropoietin in Malaysia to treat end-stage renal failure patients [1]. Since CCM Duopharma co-developed the product with PanGen, the company has exclusive rights to the Malaysia, Singapore and Brunei markets. CCM Duopharma plans to start marketing the drug as of April 2019. The two companies are also targeting other ASEAN (Association of Southeast Asian Nations) markets. PanGen has signed deals in Thailand and Turkey, and is in talks with Saudi Arabia and the Middle East.

According to its biosimilar pipeline, PanGen has submitted an application for approval of its epoetin alfa biosimilar (PDA10) in South Korea, and is also working on biosimilars of Factor VIII (PGA40) and granulocyte colony-stimulating factor (G-CSF) (PHA30).

There are already three epoetin alfa and two epoetin zeta biosimilars approved in the European Union. Retacrit and Silapo (epoetin zeta), as well as Abseamed, Binocrit and Epoetin alfa Hexal (epoetin alfa), were all approved in 2007. One epoetin alfa biosimilar, Retacrit (epoetin alfa-epbx), has also been approved in the US.

Related article
Biosimilars of epoetin alfa

References
1. GaBI Online - Generics and Biosimilars Initiative. Asian companies venture into biosimilars for kidney failure [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Feb 15]. Available from: www.gabionline.net/Biosimilars/News/Asian-companies-venture-into-biosimilars-for-kidney-failure

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Korea Biomedical Review, PanGen

comment icon Comments (0)
Post your comment
Related content
Canada approves adalimumab and bevacizumab biosimilars
Health Canada V13I20
Biosimilars/News Posted 22/10/2021
EMA recommends approval of two adalimumab biosimilars
ST002293
Biosimilars/News Posted 01/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010